About Intersect ENT
Intersect ENT is a company based in Menlo Park (United States) founded in 2003 was acquired by Medtronic in August 2021. Intersect ENT has raised $76.53 million across 4 funding rounds from investors including Medtronic, Kleiner Perkins and Norwest Venture Partners. The company has 371 employees as of December 31, 2022. Intersect ENT has completed 1 acquisition, including Fiagon. Intersect ENT operates in a competitive market with competitors including Tivic Health, Acclarent, Entellus Medical, MyPurMist and Dalent Medical, among others.
- Headquarter Menlo Park, United States
- Employees 371 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$76.53 M (USD)
in 4 rounds
-
Latest Funding Round
$65 M (USD), Post-IPO
May 11, 2020
-
Investors
Medtronic
& 5 more
-
Employee Count
371
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Medtronic
(Aug 06, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Intersect ENT
Unlock access to complete
Unlock access to complete
Software Development Team
362 people
Leadership Team
153 people
Sales and Marketing
123 people
Senior Team
61 people
Product Management Team
61 people
Finance and Accounting
52 people
Human Resources and Administration
40 people
Principal Team
28 people
Unlock access to complete
Funding Insights of Intersect ENT
Intersect ENT has successfully raised a total of $76.53M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intersect ENT
Intersect ENT has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Kleiner Perkins and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked | |
|
VC firm that focuses on early stage investments in the US
|
Locked | Locked | Locked |
Investor details for Intersect ENT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intersect ENT
Intersect ENT has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fiagon.
Investment portfolio details for Intersect ENT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Clinical navigation systems for surgical applications to healthcare providers
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Intersect ENT
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Intersect ENT
Detailed financials for Intersect ENT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intersect Ent Comparisons
Peer comparison for Intersect ENT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intersect ENT
Intersect ENT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tivic Health, Acclarent, Entellus Medical, MyPurMist and Dalent Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Bioelectronic devices for sinusitis pain relief are developed.
|
|
| Locked | Locked | Locked |
Balloon-based sinuplasty technologies are developed for ENT surgeons.
|
|
| Locked | Locked | Locked |
Minimally invasive products for chronic sinusitis treatment are developed.
|
|
| Locked | Locked | Locked |
Medical humidification devices are developed with patented CFV technology.
|
|
| Locked | Locked | Locked |
Balloon-based sinus dilation devices are developed for sinusitis treatment.
|
Detailed competitors of Intersect ENT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intersect Ent
Complete news archive for Intersect ENT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intersect ENT
Intersect ENT was founded in 2003 and raised its 1st funding round 7 years after it was founded.
Intersect ENT is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Intersect ENT is a funded company, having raised a total of $76.53M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Intersect ENT is 371.
Developer of a drug-releasing implant to treat sinusitis. The company has developed drug-releasing implants called CE marked and FDA-approved dissolvable implants for the treatment of chronic sinusitis called Propel, Propel Mini and PROPEL Contour. The devices consist of a spring-like implant that expands to open the ethmoid sinus and dissolves to deliver corticosteroids with anti-inflammatory properties to the sinus lining. The company claims that the device is clinically proven to prevent obstruction of the ethmoid sinus following surgery.
Intersect ENT's top competitors include Tivic Health, Entellus Medical and MyPurMist.
Intersect ENT has made 1 acquisition, including Fiagon.
Intersect ENT has 6 investors. Key investors include Medtronic, Kleiner Perkins, Norwest Venture Partners, PTV Healthcare Capital, and Deerfield.